Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.

ABSTRACT: Available cholinergic drugs for treating Alzheimer's disease (AD) provide modest symptomatic benefit. We hypothesized that co-administration of a peripheral anticholinergic to reduce dose-limiting adverse effects (AEs) would enable the safe/tolerable use of higher cholinesterase inhibitor doses and thus improve their antidementia efficacy. A modified single-blind, ascending-dose, phase IIa study of donepezil plus solifenacin (CPC-201) lasting 26 weeks was conducted in 41 patients with probable AD of moderate severity. Entry criteria included the use of donepezil at a dose of 10 mg/day during the preceding 3 months. The primary outcome measure was the maximum tolerated dose (MTD) of donepezil achieved (to protocol limit of 40 mg/day) when administered with the anticholinergic solifenacin 15 mg/day. Secondary measures included assessments of cognitive and global function, as well as of AEs. The mean?±?SD donepezil MTD increased to 38?±?0.74 mg/day (median 40 mg/day; p?

SUBMITTER: Chase TN 

PROVIDER: S-EPMC5398986 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature